DexCom, Inc. logo
DexCom, Inc. (DXCM)
Compare

DexCom, Inc. (DXCM) PS Ratio: 6.18

Is DexCom, Inc.’s P/S ratio high or low?

DexCom, Inc.'s P/S ratio of 6.18 is 54% below its 5-year average of 13.46, near the low end of its 5-year range (4.72–30.21).

The P/S ratio for DexCom, Inc. (DXCM) is 6.18 as of Wednesday, June 10, 2026. It is below its 12-month average by 3.90% (6.43).

DXCM PS Ratio Chart

DXCM PS Ratio
6.18-25.81% 1Y
Zoom

DXCM Average PS Ratio Chart

DXCM Current vs Average PS Ratio Chart

DXCM PS Ratio Metrics

PS RATIO

6.18

PS RATIO AVG TTM

6.43

PS RATIO AVG 3Y

9.81

PS RATIO AVG 5Y

13.46

PS RATIO AVG 10Y

13.68

PS RATIO AVG 15Y

14.08

PS RATIO AVG 20Y

153.99

CURRENT VS TTM AVG

-3.90%

CURRENT VS 3Y AVG

-36.97%

CURRENT VS 5Y AVG

-54.07%

CURRENT VS 10Y AVG

-54.82%

CURRENT VS 15Y AVG

-56.10%

CURRENT VS 20Y AVG

-95.99%

DXCM Competitors' PS Ratio

NAMEMARKET CAPPS RATIOTTM3Y5Y
DexCom, Inc. (DXCM)6.186.439.8113.46
Biogen Inc. (BIIB)$29.00B2.962.432.853.13
IQVIA Holdings Inc. (IQV)$30.60B1.872.072.422.72
Veeva Systems Inc. (VEEV)$26.73B8.1913.0513.7616.18
Centene Corporation (CNC)$31.94B0.160.110.190.25
Zoetis Inc. (ZTS)$34.20B3.626.108.199.35
Waters Corporation (WAT)$23.83B7.976.606.586.83
Mettler-Toledo International Inc. (MTD)$22.85B5.616.806.987.67
BioNTech SE (BNTX)$21.81B6.647.566.755.47
Agilent Technologies, Inc. (A)$37.17B5.175.305.535.97

P/S vs. its own history

At 6.18, P/S is cheaper than usual — richer than 3% of its 20-year range.

20-year low

4.72

median

15.48

20-year high

29128.47

cheaperricher

Sales Valuation

P/S Ratio

6.18

Market Cap / Annual Revenue

DexCom, Inc. PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

DexCom, Inc. PS Ratio FAQ

What is the P/S ratio for DexCom, Inc. (DXCM)?
The P/S ratio for DXCM stock is 6.18.
Is DexCom, Inc.'s P/S ratio high or low?
DexCom, Inc.'s P/S ratio of 6.18 is 54% below its 5-year average of 13.46, near the low end of its 5-year range (4.72–30.21).
What is the TTM average P/S ratio for DexCom, Inc. (DXCM)?
The TTM average P/S ratio for DXCM stock is 6.43.
What is the 3Y average P/S ratio for DexCom, Inc. (DXCM)?
The 3Y average P/S ratio for DXCM stock is 9.81.
What is the 5Y average P/S ratio for DexCom, Inc. (DXCM)?
The 5Y average P/S ratio for DXCM stock is 13.46.
What is the 10Y average P/S ratio for DexCom, Inc. (DXCM)?
The 10Y average P/S ratio for DXCM stock is 13.68.
What is the 15Y average P/S ratio for DexCom, Inc. (DXCM)?
The 15Y average P/S ratio for DXCM stock is 14.08.
What is the 20Y average P/S ratio for DexCom, Inc. (DXCM)?
The 20Y average P/S ratio for DXCM stock is 153.99.

DexCom, Inc. PS Ratio History

DATEPS RATIO
2026-06-106.18
2026-06-096.39
2026-06-086.26
2026-06-055.95
2026-06-045.93
2026-06-035.94
2026-06-026.00
2026-06-016.12
2026-05-296.02
2026-05-285.91
2026-05-275.74
2026-05-265.88
2026-05-225.89
2026-05-215.87
2026-05-205.84
2026-05-195.47
2026-05-185.32
2026-05-155.03
2026-05-144.72
2026-05-134.78
2026-05-124.99
2026-05-114.85
2026-05-084.95
2026-05-074.98
2026-05-064.93
2026-05-054.86
2026-05-044.90
2026-05-015.01
2026-04-304.86
2026-04-294.93
2026-04-285.08
2026-04-275.25
2026-04-245.27
2026-04-235.36
2026-04-225.43
2026-04-215.36
2026-04-205.53
2026-04-175.47
2026-04-165.24
2026-04-155.27
2026-04-145.39
2026-04-135.40
2026-04-105.48
2026-04-095.62
2026-04-085.63
2026-04-075.40
2026-04-065.41
2026-04-025.32
2026-04-015.34
2026-03-315.37
2026-03-305.30
2026-03-275.33
2026-03-265.65
2026-03-255.72
2026-03-245.70
2026-03-235.64
2026-03-205.73
2026-03-195.76
2026-03-185.79
2026-03-175.76
2026-03-165.68
2026-03-135.50
2026-03-125.58
2026-03-115.67
2026-03-105.80
2026-03-095.88
2026-03-065.83
2026-03-056.05
2026-03-046.24
2026-03-036.25
2026-03-026.31
2026-02-276.28
2026-02-266.36
2026-02-256.26
2026-02-246.25
2026-02-236.27
2026-02-206.25
2026-02-196.18
2026-02-186.23
2026-02-176.03
2026-02-135.99
2026-02-125.57
2026-02-116.15
2026-02-106.15
2026-02-096.33
2026-02-066.31
2026-02-056.31
2026-02-046.39
2026-02-036.46
2026-02-026.54
2026-01-306.59
2026-01-296.68
2026-01-286.62
2026-01-276.65
2026-01-266.62
2026-01-236.57
2026-01-226.67
2026-01-216.51
2026-01-206.38
2026-01-166.27
2026-01-156.25
2026-01-146.29
2026-01-136.34
2026-01-126.40
2026-01-096.08
2026-01-086.17
2026-01-076.32
2026-01-066.31
2026-01-056.10
2026-01-026.00
2025-12-315.99
2025-12-306.05
2025-12-296.09
2025-12-266.10
2025-12-246.08
2025-12-236.03
2025-12-226.08
2025-12-195.96
2025-12-185.95
2025-12-175.93
2025-12-165.99
2025-12-155.93
2025-12-126.04
2025-12-116.22
2025-12-106.09
2025-12-095.98
2025-12-085.92
2025-12-055.91
2025-12-045.89
2025-12-035.85
2025-12-025.81
2025-12-015.73
2025-11-285.73
2025-11-265.64
2025-11-255.57
2025-11-245.61
2025-11-215.43
2025-11-205.27
2025-11-195.39
2025-11-185.43
2025-11-175.28
2025-11-145.24
2025-11-135.39
2025-11-125.38
2025-11-115.24
2025-11-104.95
2025-11-074.96
2025-11-065.23
2025-11-055.35
2025-11-045.52
2025-11-035.45
2025-10-315.25
2025-10-306.15
2025-10-296.47
2025-10-286.57
2025-10-276.70
2025-10-246.68
2025-10-236.74
2025-10-226.71
2025-10-216.62
2025-10-206.49
2025-10-176.32
2025-10-166.30
2025-10-156.21
2025-10-146.28
2025-10-136.19
2025-10-106.18
2025-10-096.46
2025-10-086.43
2025-10-076.27
2025-10-066.30
2025-10-036.36
2025-10-026.31
2025-10-016.27
2025-09-306.39
2025-09-296.31
2025-09-266.37
2025-09-256.48
2025-09-246.41
2025-09-236.47
2025-09-226.60
2025-09-196.40
2025-09-187.19
2025-09-177.26
2025-09-167.27
2025-09-157.17
2025-09-127.23
2025-09-117.21
2025-09-107.21
2025-09-097.44
2025-09-087.40
2025-09-057.64
2025-09-047.67
2025-09-037.49
2025-09-027.05
2025-08-297.15
2025-08-287.13
2025-08-277.25
2025-08-267.22
2025-08-257.21
2025-08-227.81
2025-08-217.65
2025-08-207.75
2025-08-197.68
2025-08-187.67
2025-08-157.68
2025-08-147.59
2025-08-137.59
2025-08-127.61
2025-08-117.39
2025-08-087.48
2025-08-077.25
2025-08-067.25
2025-08-057.16
2025-08-047.24
2025-08-017.52
2025-07-317.67
2025-07-308.45
2025-07-298.78
2025-07-288.80
2025-07-258.74
2025-07-248.52
2025-07-238.49
2025-07-228.36
2025-07-218.26
2025-07-188.24
2025-07-178.26
2025-07-168.26
2025-07-158.33
2025-07-148.38
2025-07-118.19
2025-07-108.40
2025-07-098.34
2025-07-088.23
2025-07-078.15
2025-07-038.15
2025-07-028.21
2025-07-018.21
2025-06-308.58
2025-06-278.48
2025-06-268.35
2025-06-258.32
2025-06-248.60
2025-06-237.84
2025-06-207.86
2025-06-187.96
2025-06-178.04
2025-06-168.15
2025-06-138.05
2025-06-128.14
2025-06-118.15
2025-06-108.33
2025-06-098.42
2025-06-068.51
2025-06-058.42
2025-06-048.41
2025-06-038.53
2025-06-028.40
2025-05-308.43
2025-05-298.34

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

San Diego, CA
10,200 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Jacob Steven Leach